Bayer AG

With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey

Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx 

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more

Plus: CMO changes at Sunbird and Cidara, and updates from Aicuris, Renovaro, Noema and more

Plus: Tanya Wallace to head of neuroscience and ophthalmology at AbbVie, and updates from Editas and Zentalis

But they agree that creating a reliable product is necessary for scalability

Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more

Plus: Heather Turner to lead neurology play LB, and updates from Mirai Bio and Diakonos

The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2

Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ